They have a number of items in the drug pipeline, not just one or two, more like 5 or 6 now, IIRC. The float is itty bitty right now, The entire OS is tiny, and the CEO owns and controls about 60-80% of those shares last time I looked (I think he directly owns over 50%, and a company he controls via controlling ownership owns maybe another 20%) that is why the trading volume this year is nearly zero. The fact that he stepped in set a bottom by repeatedly buying more shares at $2.25 I think is strong statement.
They have enough cash to operate the company at a loss for several years unless they jump into several Phase III drug trials, which I do not see coming any time soon.
Biotechs can rally for poor reasons, and this one looks like it has bottomed to me. All the old investors from last year are in at over $20/share in terms of old shares from the R/S, buyout. So you do the math!!!!
Market Data 
Markets 
AI
